ImmuneAGE Bio operates in the biotechnology sector, focusing on drug discovery for immune system rejuvenation. The company has developed a unique platform that enables the expansion and rejuvenation of hematopoietic stem cells (HSCs) from the bone marrow by 1,000 times, which is unprecedented in the field. This technology not only facilitates better bone marrow transplants but also allows for high throughput drug screening on human HSCs. ImmuneAGE Bio serves clients in the healthcare and pharmaceutical industries, particularly those involved in stem cell research and regenerative medicine. The company generates revenue through partnerships, licensing agreements, and the sale of its proprietary assays and drug discovery services. By targeting cellular aging and immune cell aging, ImmuneAGE Bio aims to create a future where populations are more resistant to pandemics and cancer, ultimately reducing hospital time and maximizing healthy, productive years of life.

Keywords: biotechnology, drug discovery, immune system, stem cells, hematopoietic, rejuvenation, bone marrow, regenerative medicine, high throughput screening, cellular aging.